- Home
- URGN vs PSFE Comparison
URGN vs PSFE Comparison
Compare URGN & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- PSFE
- Stock Information
- Founded
- URGN 2004
- PSFE 1996
- Country
- URGN United States
- PSFE United Kingdom
- Employees
- URGN N/A
- PSFE N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- PSFE Business Services
- Sector
- URGN Health Care
- PSFE Consumer Discretionary
- Exchange
- URGN Nasdaq
- PSFE Nasdaq
- Market Cap
- URGN 896.3M
- PSFE 770.1M
- IPO Year
- URGN 2017
- PSFE N/A
- Fundamental
- Price
- URGN $19.44
- PSFE $14.16
- Analyst Decision
- URGN Strong Buy
- PSFE Sell
- Analyst Count
- URGN 8
- PSFE 4
- Target Price
- URGN $28.50
- PSFE $17.38
- AVG Volume (30 Days)
- URGN 1.0M
- PSFE 400.9K
- Earning Date
- URGN 08-07-2025
- PSFE 08-12-2025
- Dividend Yield
- URGN N/A
- PSFE N/A
- EPS Growth
- URGN N/A
- PSFE N/A
- EPS
- URGN N/A
- PSFE N/A
- Revenue
- URGN $94,238,000.00
- PSFE $1,676,391,000.00
- Revenue This Year
- URGN $39.80
- PSFE $3.06
- Revenue Next Year
- URGN $108.94
- PSFE $6.77
- P/E Ratio
- URGN N/A
- PSFE N/A
- Revenue Growth
- URGN 10.85
- PSFE 0.47
- 52 Week Low
- URGN $3.42
- PSFE $10.63
- 52 Week High
- URGN $21.02
- PSFE $26.25
- Technical
- Relative Strength Index (RSI)
- URGN 58.49
- PSFE 59.37
- Support Level
- URGN $18.65
- PSFE $13.02
- Resistance Level
- URGN $20.11
- PSFE $13.98
- Average True Range (ATR)
- URGN 1.20
- PSFE 0.78
- MACD
- URGN -0.24
- PSFE 0.15
- Stochastic Oscillator
- URGN 60.08
- PSFE 90.55
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.